Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
حداقل ۳ — حداکثر ۲۰ • واحد: g/dL
حداقل ۰ — حداکثر ۱۰۰ • واحد: %
حداقل ۱ — حداکثر ۲۰۰۰ • واحد: ×10⁹/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–10.99
- Intermediate-1 Risk11–13.99
- Intermediate-2 Risk14–15.99
- High Risk16–50
The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) calculates predicting survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). Key inputs include age years. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.
Clinical Indication
The Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is indicated for bedside clinical practice to support Predicts survival in patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET). This specialized prognostic model was developed specifically for secondary myelofibrosis, incorporating clinical parameters and molecular genetic information to provide superior risk stratification compared to models designed for primary myelofibrosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: The model has been validated in multiple cohorts and is adopted by NCCN and European guidelines.
MYSEC-PM Score = (Age × 0.15) + (Hemoglobin <11 g/dL × 2) + (Circulating blasts ≥3% × 2) + (Platelet count <150 × 1) + (Constitutional symptoms × 1) + (CALR unmutated × 2)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_years | integer | Yes | Patient age in years. Age is a continuous variable in MYSEC-PM, contributing 0.15 points per year(years) |
| hemoglobin | float | Yes | Hemoglobin level in g/dL. Levels <11 g/dL indicate severe anemia and contribute 2 points to risk score(g/dL) |
| circulating_blasts | float | Yes | Percentage of circulating blasts in peripheral blood. ≥3% indicates disease progression and contributes 2 points(%) |
| platelet_count | float | Yes | Platelet count in ×10⁹/L. Count <150 indicates thrombocytopenia and contributes 1 point to risk score(×10⁹/L) |
| constitutional_symptoms | string | Yes | Presence of constitutional symptoms (weight loss >10% in 6 months, night sweats, fever). Indicates systemic disease burden and contributes 1 point |
| calr_mutation_status | string | Yes | CALR (Calreticulin) mutation status. Unmutated CALR is associated with poor prognosis and contributes 2 points to risk score |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–10.99 | Low Risk | Low risk secondary myelofibrosis |
| 11–13.99 | Intermediate-1 Risk | Intermediate-1 risk secondary myelofibrosis |
| 14–15.99 | Intermediate-2 Risk | Intermediate-2 risk secondary myelofibrosis |
| 16–50 | High Risk | High risk secondary myelofibrosis |
Evidence-Based References (EBM)
- Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726-2731. doi: 10.1038/leu.2017.169.DOI: 10.1038/leu.2017.169
- Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91(9):918-22. doi: 10.1002/ajh.24423.DOI: 10.1002/ajh.24423
- Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867.DOI: 10.1200/JCO.2018.78.9867